


- 4 -

Amendments to the Claims:

The listing of claims will replace all prior versions and listing of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A compound represented by the structural formula:



Formula I

wherein:

X is CH or N;

Y is selected from the group consisting of C, CH or N, and when Y is CH or N, the optional covalent bond (represented by the dotted line between rings II and IV) is absent, and when Y is C, that optional covalent bond is present;

G is $(\text{CHR}^4)_n$ or $\text{C}(=\text{O})$;

R is alkyl substituted with a six-membered heterocyclyl with one N as the only ring heteroatom selected from the group consisting of alkyl, OR^4 , aryl, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclioxy, cycloalkyl, cycloalkyloxy, $\text{N}(\text{R}^4)_2$ where the two R^4 moieties can be the same or different, $(\text{CH}_2)_n$ -aryl, $(\text{CH}_2)_n$ -heteroaryl, $(\text{CH}_2)_n$ -heterocyclyl and

- 5 -

~~-(CH₂)_n-cycloalkyl, wherein each of said alkyl, aryl, heteroaryl, six-membered heterocyclyl and cycloalkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of alkyl, alkyl, aryl, heteroaryl, -OR⁴, heterocyclyl, heterocyclyloxy, cycloalkyl, cycloalkyloxy, -N(R⁴)₂ where the two R⁴ groups can be the same or different, -C(O)R⁴, and -C(O)N(R⁴)₂ where the two R⁴ moieties can be the same or different;~~

one of a, b, c and d in ring I represents N or N⁺O⁻, and the remaining a, b, c and d positions represent C(R¹) or C(R²); or
each of a, b, c, and d are independently selected from C(R¹) or C(R²);
R¹ and R² can be the same or different, each being independently selected from the group consisting of:

H, halo, -CF₃, -OR⁴, -C(O)R⁴, -OCF₃, -SR⁴, -S(O)_nR⁵,
~~benzotriazol-1-yloxy, tetrazol-5-ylthio,~~ alkynyl,
alkenyl wherein said alkenyl can be unsubstituted or optionally substituted with halo, -OR⁴ or -C(O)OR⁴,
alkyl wherein said alkyl can be unsubstituted or optionally substituted with halo, -OR⁴ or -C(O)OR⁴,
-N(R⁴)₂ where the two R⁴ moieties can be the same or different,
-NO₂, -OC(O)R⁵, -C(O)OR⁴, -CN, -N(R⁴)C(O)OR⁴,
-SR⁵C(O)OR⁴, and -SR⁵N(R⁴)₂ (provided that R⁵ in -SR⁵N(R⁴)₂ is not -CH₂-) wherein each R⁴ is independently selected;

the dotted line between carbon atoms 5 and 6 represents an optional bond, such that when a double bond is present, A and B can be the same or different, each being independently selected from the group consisting of -R⁴, halo, -OR⁴, -C(O)OR⁴, -OC(O)OR⁴ or -OC(O)R⁴, and when no double bond is present between carbon atoms 5 and 6, A and B can be the same or different, each being independently selected from the

- 6 -

group consisting of (H₂), -(OR⁵)₂, (H and halo), (dihalo), (H and R⁵), (R⁵)₂, (H and -OC(O)R⁴), (H and -OR⁴), (=O), and (H, (=NOR⁴) or (-O-(CH₂)_p-O-) wherein p is 2, 3 or 4);

R³ is selected from the group consisting of H, alkyl, alkoxy and alkoxyalkyl;

R⁴ is selected from the group consisting of H, alkyl, aryl and aralkyl;

R⁵ is alkyl or aryl;

R⁶ is H or alkyl;

n is a number from 1-4; and

q is a number from 1-8.

Claim 2 (original): The compound of claim 1, wherein position a in ring I is N or N⁺O⁻.

Claim 3 (original): The compound of claim 1, wherein A and B in ring II are both H₂, and the C5-C6 bridge is unsubstituted.

Claim 4 (original): The compound of claim 1, wherein R¹ and R² is each independently H or halo.

Claims 5-8: Cancelled.

Claim 9 (currently amended): The compound of claim 1, wherein R is ~~selected from the group consisting of unsubstituted alkyl, alkyl substituted with a six-membered heterocyclyl, -NH₂, and t-butoxy~~, wherein said six-membered heterocyclyl can be unsubstituted or optionally substituted with one or more moieties selected from the group consisting of -C(O)alkyl, and -C(O)N(alkyl)₂ where the two alkyl moieties can be the same or different.

Claim 10 (original): The compound of claim 1, wherein R³ is H and q is 8.

Claim 11 (original): The compound of claim 1, wherein R³ is alkyl and q is 1.

Claim 12 (original): The compound of claim 1, wherein R³ is alkoxyalkyl or aralkyl, and q is 1.

Claim 13 (original): The compound of claim 1, wherein R⁴ is H, alkyl or aryl.

Claim 14 (original): The compound of claim 1, wherein R⁵ is alkyl.

Claim 15 (original): The compound of claim 1, wherein R⁶ is H.

Claim 16 (original): The compound of claim 2, wherein position a is N.

- 7 -

Claim 17 (original): The compound of claim 1, wherein position a is N and positions b, c and d are all the same and are C(R¹).

Claim 18 (original): The compound of claim 17, wherein R¹ and R² are the same or different, each being independently selected from H, Br, F and Cl.

Claim 19 (original): The compound of claim 12, wherein R³ is selected from the group consisting of n-butyl, tert-butyl, 2-(methoxy)ethyl and benzyl, and q is 1.

Claim 20 (original): The compound of claim 13, wherein R⁴ is H.


Claim 21 (original): The compound of claim 14, wherein R⁵ is methyl.

Claim 22: Cancelled.


Claim 23 (original): The compound of claim 1, wherein n, q and p all equal 1.

Claim 24 (original): The compound of claim 1, wherein the rings I and III are:
(i) 3-Br-8-Cl-10-Br-substituted; (ii) 3-Br-7-Br-8-Cl-substituted; (iii) 3-Br-8-Cl-substituted; (iv) 3-Cl-8-Cl-substituted; (v) 3-F-8-Cl-substituted; (vi) 8-Cl-substituted; (vii) 10-Cl-substituted; (viii) 3-Cl-substituted; (ix) 3-Br-substituted; or (x) 3-F-substituted.


Claim 25 (currently amended): A compound of the formula:




- 8 -




- 9 -



- 10 -



- 11 -



Claims 26-38: Cancelled.

Claim 39 (original): A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 1 in combination with at least one pharmaceutically acceptable carrier.

Claim 40 (original): The pharmaceutical composition of claim 39, additionally comprising one or more agents selected from the group consisting of inhibitors of 5 α -reductase type 1, inhibitors of 5 α -reductase type 2, flutamide, nicalutamide, bicalutamide, LHRH agonists, LHRH antagonists, inhibitors of 17 α -hydroxylase/C17-20 lyase, inhibitors of 17 β -Hydroxysteroid dehydrogenase type 5, 17 β -Hydroxysteroid dehydrogenase/17 β -oxidoreductase isoenzymes, tamsulosin, terazosin, a potassium channel agonist, a 5 α -reductase inhibitor, a chemotherapeutic agent and a biological agent, optionally in association with at least one method selected from surgery and radiation therapy.

Claim 41 (Original): A compound of claim 1 in purified form.